Anti-Mullerian Hormone Test Market Projected to Reach $586.48 million by 2030 – Exclusive Report by 360iResearch

PUNE, India, April 26, 2024 /PRNewswire/ — The report titled Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use – Global Forecast 2024-2030 is now available on’s offering, presents an analysis indicating that the market projected to grow from a size of $274.26 million in 2023 to reach $586.48 million by 2030, at a CAGR of 11.46% over the forecast period.


Global Need for AMH Testing Grows as Reproductive Health Awareness Rises

Anti-mullerian hormone (AMH) tests are critical in assessing a woman’s remaining egg count, potential fertility, and the health of her ovaries. These tests serve vital functions in diagnosing conditions such as polycystic ovary syndrome (PCOS) and primary ovarian insufficiency, as well as in guiding treatment in various reproductive procedures, including in vitro fertilization (IVF). Challenges include high costs and a lack of widespread awareness, particularly in regions with limited resources. The global market for AMH tests is expanding, driven by increased awareness of reproductive health issues, an upward trend in the age of first-time mothers, and technological advancements that enhance the accessibility and effectiveness of these diagnostic tests. Regions such as Asia-Pacific are witnessing significant growth due to increased health expenditures, a shift toward preventive healthcare, advanced healthcare infrastructures, and a proactive approach to fertility issues supporting mature markets such as the Americas and Western Europe. Eastern Europe, the Middle East, and Africa are developing at varying rates, fueled by improvements in healthcare systems and initiatives aimed at bolstering women’s health services.

Download Sample Report @

The Crucial Role of Anti-Müllerian Hormone Testing in Addressing the Global Rise of Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is one of the prevalent endocrine diseases among women of reproductive age, affecting approximately 8% to 13% worldwide, according to the World Health Organization (WHO). This condition often leads to various symptoms due to hormonal imbalance, including menstrual irregularities and infertility, with many cases remaining undiagnosed. A key tool in identifying PCOS is the Anti-Müllerian hormone (AMH) test, which measures the levels of AMH produced by ovarian follicles. Elevated AMH levels can indicate PCOS, as women with the disorder typically exhibit a higher count of antral follicles. The increasing awareness of fertility issues and the escalating occurrences of PCOS highlight the growing need for AMH testing solutions. Healthcare providers can better manage and potentially mitigate the long-term impacts of PCOS, emphasizing the need for early interventions and promoting healthier lifestyles among affected individuals by facilitating early diagnosis through AMH tests.

Home and Clinical Testing Is On The Rise of Point-of-Care AMH Tests

Point-of-care (POC) testing for anti-Mullerian hormone (AMH) revolutionizes the approach to fertility evaluations by providing rapid results in non-traditional settings such as clinics and homes. These user-friendly tests are designed with simplicity in mind, requiring little to no prior technical expertise, and dramatically reduce the waiting period for results. This immediacy is critical in fertility treatments and ovarian function assessments, where timely decision-making is essential. For individuals assessing their fertility independently, self-check AMH kits offer the privacy and convenience of testing at home without the need for immediate professional involvement. This can be particularly valuable for those residing in remote areas or with restricted access to specialized healthcare services. Overall, POC testing empowers individuals and healthcare providers alike by streamlining fertility and ovarian reserve evaluations, blending convenience with accuracy and speed.

Request Analyst Support @

Beckman Coulter, Inc. by Danaher Corporation at the Forefront of Anti-Mullerian Hormone Test Market with a Strong 13.44% Market Share

The key players in the Anti-Mullerian Hormone Test Market include Bio-Rad Laboratories, Inc., Beckman Coulter, Inc. by Danaher Corporation, bioMérieux S.A., Thermo Fisher Scientific Inc., Siemens Healthineers AG, and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.

Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Anti-Mullerian Hormone Test Market

We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Anti-Mullerian Hormone Test Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Anti-Mullerian Hormone Test Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.

Ask Question to ThinkMi @

Dive into the Anti-Mullerian Hormone Test Market Landscape: Explore 195 Pages of Insights, 368 Tables, and 24 Figures

  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Anti-Mullerian Hormone Test Market, by Product
  7. Anti-Mullerian Hormone Test Market, by End-User
  8. Anti-Mullerian Hormone Test Market, by Distribution
  9. Anti-Mullerian Hormone Test Market, by Use
  10. Americas Anti-Mullerian Hormone Test Market
  11. Asia-Pacific Anti-Mullerian Hormone Test Market
  12. Europe, Middle East & Africa Anti-Mullerian Hormone Test Market
  13. Competitive Landscape
  14. Competitive Portfolio

Inquire Before Buying @

Related Reports:

  1. Hormone Replacement Therapy Market – Global Forecast 2024-2030
  2. Human Growth Hormone Market – Global Forecast 2024-2030
  3. Synthetic Hormones Market – Global Forecast 2024-2030

About 360iResearch

Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.

We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.

Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.

Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.

Contact 360iResearch

Mr. Ketan Rohom

360iResearch Private Limited,

Office No. 519, Nyati Empress,

Opposite Phoenix Market City,

Vimannagar, Pune, Maharashtra,

India – 411014.


USA: +1-530-264-8485

India: +91-922-607-7550

To learn more, visit or follow us on LinkedIn, Twitter, and Facebook.



Cision View original content:—exclusive-report-by-360iresearch-302126078.html

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. takes no editorial responsibility for the same.